Interferon alpha-2 (IFNA2)
The protein contains 188 amino acids for an estimated molecular weight of 21550 Da.
Produced by macrophages, IFN-alpha have antiviral activities. (updated: Oct. 10, 2018)
Protein identification was indicated in the following studies:
Methods
The following articles were analysed to gather the proteome content of erythrocytes.
The gene or protein list provided in the studies were processed using the ID mapping API of Uniprot in September 2018. The number of proteins identified and mapped without ambiguity in these studies is indicated below.
Only Swiss-Prot entries (reviewed) were considered for protein evidence assignation.
| Publication | Identification 1 | Uniprot mapping 2 | Not mapped / Obsolete | TrEMBL | Swiss-Prot |
|---|---|---|---|---|---|
| Goodman (2013) | 2289 (gene list) | 2278 | 53 | 20599 | 2269 |
| Lange (2014) | 1234 | 1234 | 7 | 28 | 1224 |
| Hegedus (2015) | 2638 | 2622 | 0 | 235 | 2387 |
| Wilson (2016) | 1658 | 1528 | 170 | 291 | 1068 |
| d'Alessandro (2017) | 1826 | 1817 | 2 | 0 | 1815 |
| Bryk (2017) | 2090 | 2060 | 10 | 108 | 1942 |
| Chu (2018) | 1853 | 1804 | 55 | 362 | 1387 |
1 as available in the article and/or in supplementary material
2 uniprot mapping returns all protein isoforms as one entry
The compilation of older studies can be retrieved from the Red Blood Cell Collection database.
The data and differentiation stages presented below come from the proteomic study and analysis performed by our partners of the GReX consortium, more details are available in their published work.
(right-click above to access to more options from the contextual menu)
| Variant | Description |
|---|---|
| dbSNP:rs35971916 | |
| alpha-2B and alpha-2C | |
| alpha-2C | |
| a breast cancer sample; somatic mutation |
No binding partner found
Biological Process
Adaptive immune response
Apoptotic process
B cell differentiation
B cell proliferation
Blood coagulation
Cell surface receptor signaling pathway
Cell-cell signaling
Cytokine-mediated signaling pathway
Defense response to virus
Humoral immune response
Inflammatory response
Natural killer cell activation involved in immune response
Negative regulation of gene expression
Negative regulation of interleukin-13 production
Negative regulation of interleukin-13 secretion
Negative regulation of interleukin-5 production
Negative regulation of interleukin-5 secretion
Negative regulation of T cell differentiation
Negative regulation of T-helper 2 cell cytokine production
Negative regulation of transcription, DNA-templated
Negative regulation of viral entry into host cell
Positive regulation of peptidyl-serine phosphorylation of STAT protein
Positive regulation of phosphorylation
Positive regulation of transcription, DNA-templated
Positive regulation of tyrosine phosphorylation of STAT protein
Response to exogenous dsRNA
T cell activation involved in immune response
Type I interferon signaling pathway
Cellular Component
Collagen-containing extracellular matrix
Extracellular region
Extracellular space
The reference OMIM entry for this protein is 147562
Interferon, alpha-2; ifna2
GENE FUNCTION
The successful use of intranasal alpha-2-interferon produced by recombinant DNA technology in the prophylaxis of the common cold was reported by Douglas et al. (1986) and Hayden et al. (1986). Ezekowitz et al. (1992) demonstrated the usefulness of recombinant alpha-interferon (interferon alfa-2a) for inducing regression of life-threatening corticosteroid-resistant hemangiomas in infancy. The hemangiomas treated were those that impair the function of vital structures or cause life-endangering complications such as thrombocytopenic coagulopathy with giant hemangioma (Kasabach-Merritt syndrome; 141000). The authors published 2 detailed errata clarifying and correcting numerous ambiguities and errors. Dithmar et al. (2000) showed the usefulness of recombinant alpha-interferon (IFN alfa-2b) for decreasing hepatic metastases from intraocular melanoma in a murine model. The authors concluded that adjuvant recombinant IFN alfa-2b treatment given before or at the time of enucleation might be a treatment option for patients with uveal melanoma (155720) with high-risk factors for developing metastatic disease. IFN alfa-2b is used to treat high-risk cutaneous melanomas (155600), although IFN alfa therapy is associated with a number of systemic side effects, including a flu-like syndrome, fatigue, malaise, weight loss, depression, nausea, anorexia, diarrhea, neutropenia, and thrombocytopenia. Hejny et al. (2001) reported 7 patients who developed retinopathy while receiving high-dose IFN alfa-2b therapy for adjuvant treatment of high-risk cutaneous melanoma. The risk of retinopathy appeared to be greater with higher dosage therapy and caused severe vision loss in 2 patients. The authors concluded that patients receiving high-dose IFN alfa-2b therapy need to be monitored for sequelae, including retinal neovascularization, until the retinopathy has resolved.MAPPING
The IFNA2 gene was positioned in the cluster of interferon genes on chromosome 9p22 by deletion mapping (Olopade et al., 1992). ... More on the omim web site
June 30, 2020: Protein entry updated
Automatic update: OMIM entry 147562 was added.
Oct. 19, 2018: Additional information
Initial protein addition to the database. This entry was referenced in Bryk and co-workers. (2017).